Perspective

Published on 03 Mar 2023

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective

in Pharmacology of Anti-Cancer Drugs

Ravindhi Murphy
Sarah Halford
Stefan Nicholas Symeonides

Frontiers in Oncology

doi 10.3389/fonc.2023.1144056

12,552 views
22 citations

Clinical Trial

Published on 24 Feb 2023

Perioperative lidocaine and dexmedetomidine intravenous infusion reduce the serum levels of NETs and biomarkers of tumor metastasis in lung cancer patients: A prospective, single-center, double-blinded, randomized clinical trial

in Pharmacology of Anti-Cancer Drugs

Baiqing Ren
Muqiao Cheng
Chao Liu
Huiwen Zheng
Jingyue Zhang
Wei Chen
Jie Song
Jingwen Zhuang
Tianya Liu
Rui Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1101449

3,881 views
12 citations

Review

Published on 23 Feb 2023

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases

in Pharmacology of Anti-Cancer Drugs

Enrico La Spina
Sebastiano Giallongo
Cesarina Giallongo
Nunzio Vicario
Andrea Duminuco
Rosalba Parenti
Rosario Giuffrida
Lucia Longhitano
Giovanni Li Volti
Daniela Cambria

Frontiers in Oncology

doi 10.3389/fonc.2023.1141610

2,740 views
3 citations

Review

Published on 23 Feb 2023

Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

in Pharmacology of Anti-Cancer Drugs

Junyi An
Xiaohua Hu
Feng Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1114621

2,282 views
3 citations

Editorial

Published on 22 Feb 2023

Editorial: Discovery of small molecule lead compounds: A driving force to unravel new anticancer targets and mechanisms

in Pharmacology of Anti-Cancer Drugs

Yan Zhang
Leilei Fu
Muhammad Umer Farooq Awan

Frontiers in Oncology

doi 10.3389/fonc.2023.1117660

918 views

Editorial

Published on 22 Feb 2023

Editorial: Drug-resistance in cancer cells: A new wine in an old bottle

in Pharmacology of Anti-Cancer Drugs

Leonardo Marques da Fonseca
Takeo Tatsuta
Seung-Yeol Park
Leonardo Freire-de-Lima

Frontiers in Oncology

doi 10.3389/fonc.2023.1161008

742 views

Original Research

Published on 15 Feb 2023

Unveiling the therapeutic potential of cabozantinib-loaded poly D,L-lactic-co-glycolic acid and polysarcosine nanoparticles in inducing apoptosis and cytotoxicity in human HepG2 hepatocellular carcinoma cell lines and in vivo anti-tumor activity in SCID female mice

in Pharmacology of Anti-Cancer Drugs

Sankha Bhattacharya
Vipan Kumar Parihar
Bhupendra G. Prajapati

Frontiers in Oncology

doi 10.3389/fonc.2023.1125857

3,860 views
8 citations

Editorial

Published on 15 Feb 2023

Editorial: Targeting cancer cell intracellular metabolism as a strategy against therapy resistance

in Pharmacology of Anti-Cancer Drugs

Lingling Liu
Xiaohong Cai
Yuan Zhou
Chengsi He
Hongsheng Li
Xiangfu Liu
Zhengzhi Zou

Frontiers in Oncology

doi 10.3389/fonc.2023.1144821

1,099 views
1 citation

Review

Published on 14 Feb 2023

Plant-derived natural products and combination therapy in liver cancer

in Pharmacology of Anti-Cancer Drugs

Yuqin Wang
Jinyao Li
Lijie Xia

Frontiers in Oncology

doi 10.3389/fonc.2023.1116532

4,694 views
6 citations

Original Research

Published on 10 Feb 2023

Blood-tumor barrier opening by MRI-guided transcranial focused ultrasound in a preclinical breast cancer brain metastasis model improves efficacy of combinatorial chemotherapy

in Pharmacology of Anti-Cancer Drugs

Tasneem A. Arsiwala
Kathryn E. Blethen
Cullen P. Wolford
Dhruvi M. Panchal
Samuel A. Sprowls
Ross A. Fladeland
Brooke N. Kielkowski
Trenton A. Pritt
Peng Wang
Olivia Wilson

Frontiers in Oncology

doi 10.3389/fonc.2023.1104594

2,912 views
5 citations

Original Research

Published on 09 Feb 2023

RNF6 activates TGF-β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma

in Pharmacology of Anti-Cancer Drugs

Jingge Cheng
Kun Wu
Qian Yang
Ziming Zhu
Hongye Zhao

Frontiers in Oncology

doi 10.3389/fonc.2023.1081333

1,710 views
2 citations

Systematic Review

Published on 09 Feb 2023

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Xiao Wei
Mingzhu Song
Chan Huang
Qiao Yu
Guirong Jiang
Guanghao Jin
Xibiao Jia
Zheng Shi

Frontiers in Oncology

doi 10.3389/fonc.2023.1062885

2,699 views
2 citations

Original Research

Published on 09 Feb 2023

Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies

in Pharmacology of Anti-Cancer Drugs

Jian He
Nianxiang Qiu
Xianchao Zhou
Mei Meng
Zixue Liu
Jingquan Li
Shiyu Du
Zhiqiang Sun
Hui Wang

Frontiers in Oncology

doi 10.3389/fonc.2022.1007653

2,614 views
3 citations

Systematic Review

Published on 07 Feb 2023

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Beibei Yang
Bing Wang
Yongbang Chen
Ning Wan
Fei Xie
Ning Yang
Liqing Lu
Weibin Xiao
Jin Yuan
Jian Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1044327

8,857 views
4 citations

Review

Published on 06 Feb 2023

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

in Pharmacology of Anti-Cancer Drugs

Fang Cheng
Qiling Xu
Qiang Li
Zheng Cui
Weiming Li
Fang Zeng

Frontiers in Oncology

doi 10.3389/fonc.2023.1113462

12,288 views
6 citations

Original Research

Published on 06 Feb 2023

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Bo Jiang
Junyuan Qi
Mingyuan Sun
Weiwei Zheng
Yongyue Wei
Jianxiang Wang
Fengkui Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1101738

2,221 views
6 citations

Navigation group

Articles

Project Optimus, an FDA initiative: Considerations for cancer drug development internationally, from an academic perspective

Perioperative lidocaine and dexmedetomidine intravenous infusion reduce the serum levels of NETs and biomarkers of tumor metastasis in lung cancer patients: A prospective, single-center, double-blinded, randomized clinical trial

Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases

Current understanding of cancer stem cells: Immune evasion and targeted immunotherapy in gastrointestinal malignancies

Editorial: Discovery of small molecule lead compounds: A driving force to unravel new anticancer targets and mechanisms

Editorial: Drug-resistance in cancer cells: A new wine in an old bottle

Unveiling the therapeutic potential of cabozantinib-loaded poly D,L-lactic-co-glycolic acid and polysarcosine nanoparticles in inducing apoptosis and cytotoxicity in human HepG2 hepatocellular carcinoma cell lines and in vivo anti-tumor activity in SCID female mice

Editorial: Targeting cancer cell intracellular metabolism as a strategy against therapy resistance

Plant-derived natural products and combination therapy in liver cancer

Blood-tumor barrier opening by MRI-guided transcranial focused ultrasound in a preclinical breast cancer brain metastasis model improves efficacy of combinatorial chemotherapy

RNF6 activates TGF-β1/c-Myb pathway to promote EMT in esophageal squamous cell carcinoma

Effectiveness, safety and pharmacokinetics of Polo-like kinase 1 inhibitors in tumor therapy: A systematic review and meta-analysis

Resveratrol analog, triacetylresveratrol, a potential immunomodulator of lung adenocarcinoma immunotherapy combination therapies

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis

Adverse reactions after treatment with dasatinib in chronic myeloid leukemia: Characteristics, potential mechanisms, and clinical management strategies

Pharmacokinetics of single- and multiple-dose flumatinib in patients with chronic phase chronic myeloid leukemia